| This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects (NCT07304791) | Beam Therapeutics Inc. | 2025-10-27 |
| A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants (NCT07222709) | AbbVie | 2025-10-27 |
| A Study of 177Lu-PSMA-617 in People With Gliomas (NCT07223034) | Memorial Sloan Kettering Cancer Center | 2025-10-27 |
| Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D) (NCT07226297) | n-Lorem Foundation | 2025-10-27 |
| A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (NCT07381829) | HC Biopharma Inc. | 2025-10-27 |
| A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity (NCT07232732) | Eli Lilly and Company | 2025-10-27 |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. (NCT07641634) | Prolium Bioscience, Inc | 2025-10-27 |
| UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (NCT07109986) | Nanjing IASO Biotechnology Co., Ltd. | 2025-10-27 |
| To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (NCT07259330) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2025-10-27 |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (NCT06176690) | Baylor College of Medicine | 2025-10-27 |
| A Phase Ⅰ b Clinical Study of ART101 Injection (NCT07614308) | Arnatar Therapeutics, Inc. | 2025-10-27 |
| Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention (NCT07282184) | Tongji Hospital | 2025-10-26 |
| A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT07123415) | Aptabio Therapeutics, Inc. | 2025-10-24 |
| ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy (NCT07218887) | Alexion Pharmaceuticals, Inc. | 2025-10-24 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers (NCT07304687) | Chong Kun Dang Pharmaceutical | 2025-10-24 |
| PK/PD Study of IN-001 Sublingual Spray in Healthy Adults (NCT07210320) | Insignis Therapeutics, Inc. | 2025-10-24 |
| Adaptive Radiation Boost for Rectal Cancer (NCT07221058) | Fox Chase Cancer Center | 2025-10-24 |
| MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT07025564) | City of Hope Medical Center | 2025-10-24 |
| A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (NCT07256782) | Qilu Pharmaceutical Co., Ltd. | 2025-10-24 |
| A Study of LY4064809 in Healthy Adult Chinese Participants (NCT07247357) | Eli Lilly and Company | 2025-10-24 |
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders (NCT07075510) | University of Maryland, Baltimore | 2025-10-23 |
| A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma (NCT07143812) | CHA University | 2025-10-23 |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A (NCT07220564) | Novo Nordisk A/S | 2025-10-23 |
| A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. (NCT07205159) | Forte Biosciences, Inc. | 2025-10-23 |
| Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy (NCT06691165) | Glen Foster | 2025-10-23 |
| A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure (NCT07218627) | Novo Nordisk A/S | 2025-10-23 |
| Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants (NCT07223216) | Biomea Fusion Inc. | 2025-10-23 |
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) (NCT07221565) | Truway Health, Inc. | 2025-10-23 |
| A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants (NCT07220551) | UCB Biopharma SRL | 2025-10-23 |
| PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. (NCT07053072) | West China Hospital | 2025-10-23 |
| JSKN022 in Subjects With Advanced Malignant Solid Tumors (NCT07292402) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-10-23 |
| Effect of Maridebart Cafraglutide on the Heart's Electrical Activity (NCT07229157) | Amgen | 2025-10-22 |
| a Comparive Study of Ketamine-Propofol Versus Dexmedetomidine-Propofol Sedation in Pediatric Patients Undergoing Cardiac Catheterization for Device Closure of Simple Left-to-right Shunts (NCT07669012) | Ain Shams University | 2025-10-22 |
| A Study of AK138D1 in Advanced Malignant Tumors (NCT07281326) | Akeso | 2025-10-22 |
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer (NCT07027514) | Ankyra Therapeutics, Inc | 2025-10-22 |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (NCT07213791) | Eli Lilly and Company | 2025-10-22 |
| A Study of SGT-212 Gene Therapy in Friedreich's Ataxia (NCT07180355) | Solid Biosciences Inc. | 2025-10-22 |
| Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis (NCT07205081) | Attovia Therapeutics Inc | 2025-10-22 |
| Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (NCT06957431) | Washington University School of Medicine | 2025-10-22 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer (NCT07508852) | Peking University First Hospital | 2025-10-22 |
| Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma (NCT07251413) | Instituto Oncológico Dr Rosell | 2025-10-22 |
| A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors (NCT07208136) | Jemincare | 2025-10-22 |
| A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects (NCT07239973) | BrightGene Bio-Medical Technology Co., Ltd. | 2025-10-21 |
| Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain (NCT07197645) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-10-21 |
| Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma (NCT06995872) | National Cancer Institute (NCI) | 2025-10-21 |
| A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis (NCT07230353) | Xencor, Inc. | 2025-10-21 |
| A Study of ZW251 in Participants With Advanced Solid Tumors (NCT07164313) | Zymeworks BC Inc. | 2025-10-21 |
| Test-retest Study With [18F]FBB in Cardiac Amyloidosis (NCT06790394) | Lantheus Germany GmbH | 2025-10-21 |
| Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis (NCT06995651) | University of Pennsylvania | 2025-10-21 |
| Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects (NCT07301203) | Beijing Tide Pharmaceutical Co., Ltd | 2025-10-21 |
| A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses (NCT06810934) | Kara Chew | 2025-10-21 |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation (NCT07259590) | Genfleet Therapeutics (Shanghai) Inc. | 2025-10-21 |
| A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment (NCT07165002) | Eli Lilly and Company | 2025-10-20 |
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) (NCT06889168) | Columbia University | 2025-10-20 |
| Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease (NCT07157345) | Ruijin Hospital | 2025-10-20 |
| Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation (NCT05720624) | Mayo Clinic | 2025-10-20 |
| A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects (NCT07043283) | Akeso | 2025-10-20 |
| A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects (NCT07300189) | OrsoBio, Inc | 2025-10-20 |
| Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment (NCT07193147) | Gan & Lee Pharmaceuticals. | 2025-10-20 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (NCT07213609) | GlaxoSmithKline | 2025-10-20 |
| Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects (NCT07384104) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-10-19 |
| Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects (NCT07265167) | Yuhan Corporation | 2025-10-18 |
| Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (NCT06795009) | Washington University School of Medicine | 2025-10-17 |
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML (NCT06611839) | Institute of Hematology & Blood Diseases Hospital, China | 2025-10-17 |
| A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (NCT07206498) | Wayshine Biopharm, Inc. | 2025-10-17 |
| A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants (NCT07214766) | Genentech, Inc. | 2025-10-17 |
| A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease (NCT07428096) | Palisade Bio | 2025-10-17 |
| A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors (NCT07351903) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-16 |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (NCT07006727) | Novartis Pharmaceuticals | 2025-10-16 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (NCT07024615) | Astellas Pharma Global Development, Inc. | 2025-10-16 |
| A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls (NCT07217886) | Shionogi | 2025-10-16 |
| A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults (NCT07235137) | Pfizer | 2025-10-16 |
| Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors (NCT07231081) | Tcelltech Inc. | 2025-10-16 |
| Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD (NCT07178249) | Guangzhou Jiayin Biotech Ltd | 2025-10-16 |
| A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications (NCT07189949) | Jiangsu HengRui Medicine Co., Ltd. | 2025-10-16 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers (NCT07184502) | Beijing QL Biopharmaceutical Co.,Ltd | 2025-10-16 |
| TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B (NCT04843852) | University of Maryland, Baltimore | 2025-10-16 |
| Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors (NCT07215637) | Chong Kun Dang Pharmaceutical | 2025-10-16 |
| A Multiple Ascending Dose Study of LW402 in Healthy Volunteers (NCT07546149) | Shanghai Longwood Biopharmaceuticals Co., Ltd. | 2025-10-15 |
| A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors (NCT07170787) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2025-10-15 |
| A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease (NCT07214727) | Alnylam Pharmaceuticals | 2025-10-15 |
| Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects (NCT07150962) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-10-15 |
| The Effect Of Photobiomodulation On Dental Implant Survival (NCT07636265) | Nigde Omer Halisdemir University | 2025-10-15 |
| Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors (NCT07207681) | The First Hospital of Jilin University | 2025-10-15 |
| AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer (NCT07146919) | Centre Leon Berard | 2025-10-15 |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (NCT06800963) | ImmunityBio, Inc. | 2025-10-15 |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (NCT07008378) | Genentech, Inc. | 2025-10-15 |
| Tebentafusp-tebn With LDT in Metastatic UM (NCT06626516) | Thomas Jefferson University | 2025-10-15 |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (NCT07160725) | Bristol-Myers Squibb | 2025-10-15 |
| A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants (NCT07219017) | AbbVie | 2025-10-15 |
| A Comparative Study Between the Efficacy of Diode Laser and Nano-chitosan Gel on Activation of Non-vital in- Office Bleaching Agent (NCT06782087) | Misr University for Science and Technology | 2025-10-15 |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (NCT07206056) | Novartis Pharmaceuticals | 2025-10-15 |
| A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors (NCT07077434) | Bristol-Myers Squibb | 2025-10-15 |
| TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) (NCT07284277) | Clinica Universidad de Navarra, Universidad de Navarra | 2025-10-14 |
| A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants (NCT07180862) | Bio-Thera Solutions | 2025-10-14 |
| A Clinical Study to Evaluate SM17 in Healthy Participants (NCT07466940) | SinoMab BioScience Ltd | 2025-10-14 |
| Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects. (NCT07322991) | Il-Yang Pharm. Co., Ltd. | 2025-10-14 |
| A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies (NCT07231458) | Abalos Therapeutics GmbH | 2025-10-14 |
| Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions. (NCT07149220) | Ohio State University Comprehensive Cancer Center | 2025-10-14 |
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (NCT07150546) | Emory University | 2025-10-14 |